GBS Ventures

Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnology product development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.

GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.

GBS Ventures, established in 1996 and headquartered in Australia, Oceania., specializes in Late Stage Venture, Early Stage Venture, Private Equity investments across Biotechnology, Health Care, Pharmaceutical, Biopharma, Financial Services, Venture Capital, Semiconductor, Life Science, Oncology, Finance. The organization boasts a portfolio of 63 investments, with an average round size of $15.5M and 13 successful exits. Their recent investments include Humanigen, Alloy Ventures, Mitsubishi UFJ Capital, MPM Capital, Sofinnova Investments. The highest investment round they participated in was $88.3B. Among their most notable exits are Humanigen and Alloy Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.